Management of febrile neutropenia in the United Kingdom: time for a national trial?

H Innes, Lucinda Billingham, Claire Gaunt, Neil Steven, E Marshall

Research output: Contribution to journalArticle

15 Citations (Scopus)


Recent advances in febrile neutropenia (FN) have highlighted the value of risk stratification and the evolving role of oral antibiotics with early hospital discharge in low-risk patients. The aim of this study was to survey whether these advances have been translated into routine clinical practice in the UK. Questionnaires were sent to cancer clinicians across the UK to determine clinicians' routine management of FN, including use of risk stratification, antibiotic regimen and criteria for hospital discharge. In all, 128 clinicians responded, representing 50 cancer departments (83%). Only 38% of respondents stratify patients according to risk and with substantial variation in the criteria defining 'low-risk'. Furthermore, only 22% of clinicians use oral antibiotics as first-line treatment in any patients with FN, but this was significantly greater among clinicians who do compared to those who do not stratify patients by risk, 51 vs 4% (P
Original languageEnglish
Pages (from-to)1324-1328
Number of pages5
JournalBritish Journal of Cancer
Publication statusPublished - 12 Dec 2005


Dive into the research topics of 'Management of febrile neutropenia in the United Kingdom: time for a national trial?'. Together they form a unique fingerprint.

Cite this